Akilen Mechanism of Action

Pharmacology: AKILEN contains ofloxacin, a fluoroquinolone anti-bacterial agent with bactericidal activity against a wide range of Gram-negative and Gram-positive organisms and some anaerobic bacteria.
AKILEN has a bactericidal effect by inhibiting the A subunit of bacterial DNA gyrase, an enzyme responsible for the supercoiling of DNA. This interaction leads to inhibition of bacterial DNA replication.
The Gram-negative bacteria susceptible to AKILEN are as follows: E. coli, Klebsiella, Enterobacter, Proteus, Providencia, Citrobacter, Serratia, Salmonella, Shigella, Yersinia enterocolitica, Vibrio species, Legionella pneumophila, Campylobacter jejuni, Pseudomonas aeruginosa including strains that are resistant to other antibacterial agents.
The Gram-positive bacteria susceptible to AKILEN are as follows: Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus faecalis, Mycobacterium tuberculosis, certain atypical Mycobacteria and Chlamydia trachomatis are also susceptible to AKILEN.
AKILEN administered orally has better pharmacokinetics properties than ciprofloxacin, including greater bioavailability and a longer half-life.
Oral bioavailability of AKILEN is about 95%, plasma protein binding is about 8% and half-life between 5-7 hours.